Literature DB >> 31672701

Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.

Guofeng Ma1,2, Ye Liang2, Yuanbin Chen2, Liping Wang2, Dan Li2, Zhijuan Liang2, Xiao Wang1, Dongxu Tian1, Xuecheng Yang3, Haitao Niu3,2.   

Abstract

The programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) pathway plays a pivotal role in the immune escape of tumors. Many tumor cells show "glutamine dependence." However, the relationship between glutamine metabolism and PD-L1 expression has not been reported. In this study, changes in PD-L1 expression in renal carcinoma cells were evaluated during glutamine deprivation and recovery. Although PD-L1 expression differed in two renal cancer cell lines, both cell lines upregulated PD-L1 during glutamine deprivation, and the upregulated PD-L1 was restored to normal after glutamine recovery. Mechanistically, glutamine deprivation resulted in activation of EGFR signaling via ERKs 1 and 2 (ERK1/2) and c-Jun. In addition, treatment of renal cancer cells with EGF also induced PD-L1 expression and ERK1/2 phosphorylation. Finally, inhibitors of EGFR, ERK, and c-Jun all inhibited phosphorylation of c-Jun and downregulated PD-L1 expression induced by glutamine deprivation. Taken together, the data suggest that glutamine regulates the expression of PD-L1 through the EGFR/ERK/c-Jun pathway in renal cancer. IMPLICATIONS: This study reveals glutamine deprivation induces PD-L1 expression via activation of EGFR/ERK/c-Jun signaling in renal cancer and provides novel markers for the treatment of renal cancer. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31672701     DOI: 10.1158/1541-7786.MCR-19-0517

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  14 in total

Review 1.  Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Authors:  Dan-Dan Shen; Ya-Ping Bi; Jing-Ru Pang; Li-Juan Zhao; Long-Fei Zhao; Ya Gao; Bo Wang; Hui-Min Liu; Ying Liu; Ning Wang; Yi-Chao Zheng; Hong-Min Liu
Journal:  Cell Mol Life Sci       Date:  2022-07-11       Impact factor: 9.207

Review 2.  A glutamine 'tug-of-war': targets to manipulate glutamine metabolism for cancer immunotherapy.

Authors:  Laura J Pallett; Sarah Dimeloe; Linda V Sinclair; Adam J Byrne; Anna Schurich
Journal:  Immunother Adv       Date:  2021-06-01

3.  Oncogenic magnesium transporter 1 upregulates programmed death-1-ligand 1 expression and contributes to growth and radioresistance of glioma cells through the ERK/MAPK signaling pathway.

Authors:  Yuanyuan Wu; Hongbing Wang; Dongdong Wei
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC.

Authors:  Xiao Wang; Chao Liang; Xin Yao; Ruo-Han Yang; Zhan-Sheng Zhang; Fan-Ye Liu; Wen-Qi Li; Shu-Hua Pei; Jing Ma; Song-Qiang Xie; Dong Fang
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810

Review 5.  Metabolic Implications of Immune Checkpoint Proteins in Cancer.

Authors:  Elizabeth R Stirling; Steven M Bronson; Jessica D Mackert; Katherine L Cook; Pierre L Triozzi; David R Soto-Pantoja
Journal:  Cells       Date:  2022-01-05       Impact factor: 6.600

Review 6.  Microenvironmental influences on T cell immunity in cancer and inflammation.

Authors:  Darren R Heintzman; Emilie L Fisher; Jeffrey C Rathmell
Journal:  Cell Mol Immunol       Date:  2022-01-17       Impact factor: 22.096

7.  Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation.

Authors:  Jacob W Greenberg; Hogyoung Kim; Miae Ahn; Ahmed A Moustafa; He Zhou; Pedro C Barata; A Hamid Boulares; Asim B Abdel-Mageed; Louis S Krane
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639

Review 8.  Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy.

Authors:  Michaël Cerezo; Stéphane Rocchi
Journal:  Cell Death Dis       Date:  2020-11-11       Impact factor: 8.469

Review 9.  Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies.

Authors:  Guofeng Ma; Chun Li; Zhilei Zhang; Ye Liang; Zhijuan Liang; Yuanbin Chen; Liping Wang; Dan Li; Manqin Zeng; Wenhong Shan; Haitao Niu
Journal:  Front Oncol       Date:  2021-07-13       Impact factor: 6.244

Review 10.  PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.

Authors:  Lei Ding; Hui Yu Dong; Tian Ren Zhou; Yu Hao Wang; Tao Yan; Jun Chen Li; Zhong Yuan Wang; Jie Li; Chao Liang
Journal:  Cancer Med       Date:  2021-08-12       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.